Kronos Bio

Kronos Bio

  • Founded: 2017
  • Location: Cambridge, MA
  • Employee range: 50 - 200
  • Clinical stage: Clin2
  • Therapy area: Solid tumors
  • Drug types: ONC
  • Lead product: KB-0742
  • Product link:
  • Funding: $287M IPO Oct 2020; $155M Aug 2020; $105M A Jul 2019; $18M May 2018

job board

Short description:

First-in-class therapies against historically intractable targets

Drug notes:

Lanraplenib Clin1 AML; 3+ undisclosed programs RD undisclosed; Entospletinib Clin3 (discontinued Nov 2022) AML

Long description:

Kronos Bio is developing therapeutics that target dysregulated transcription that underpins most human diseases. Individual transcription factors, which dictate expression of a subset of genes, have been attractive drug targets but have achieved little success. Instead, Kronos is analyzing the total transcriptional regulatory network (TRNs) of diseased cells to identify critical nodes responsible for a transcription factor's activity. This approach circumvents the need to focus on a single transcription factor and offers many avenues to target. Kronos has identified three investigational compounds that are being investigated in cancer patients. This includes two oral SYK inhibitors. SYK is a critical node in the dysregulated TRN of acute myeloid leukemia.


Kronos Bio
Sr Director, Clinical Operations
San Mateo, CA|10 days ago

© 2024 Work In Biotech LLC
Personal data

Terms of Service

Privacy Policy